Nuo Therapeutics, PAM Health partner to advance access to wound healing therapy

A multi-year exclusive agreement between PAM Health and Nuo Therapeutics (AURX) means Nuo’s Aurix System will serve as the sole platelet-rich plasma wound care therapy across all of PAM Health’s long-term acute care hospitals, inpatient rehabilitation hospitals, and outpatient and wound care clinics. This collaboration will make advanced regenerative treatment more widely available for patients suffering from chronic non-healing wounds. “At PAM Health, we are committed to delivering clinical excellence to our patients through evidence-based, outcome-driven therapies,” said Nick Fazzolari, SVP, Chief Business Officer, PAM Health. “Adding the Aurix System to our advanced wound care services reflects our unwavering dedication to innovative, patient-centered solutions that optimize healing, reduce complications, and support long-term well-being. This collaboration is a natural extension of our mission to deliver transformative care solutions and reflects the values guiding our pursuit of excellence across the post-acute continuum.”